Studies on larger patient populations, as well as studies on the underlying pathophysiological mechanisms, could further improve the usability of CRP as a prognostic parameter in CPI therapy of R/M-HNSCC patients. This evidence concerns the gene CRP and head and neck squamous cell carcinoma.